(ADAP) Adaptimmune Therapeutics - Ratings and Ratios

Adaptimmune Therapeutics Plc (NASDAQ:ADAP) is a clinical-stage biopharmaceutical company specializing in innovative cell therapies for cancer treatment. Utilizing its proprietary SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell technology, the company engineers patients T-cells to target specific cancer antigens. Their lead candidate, ADP-A2M4, targets MAGE-A4 in solid tumors, with trials including Phase II SPEARHEAD-1 for synovial sarcoma and Phase II SURPASS-3 for platinum-resistant ovarian cancer. Additionally, Phase I trials are ongoing for head and neck, and urothelial cancers, with next-gen programs focusing on HLA-independent TCRs for solid tumors.

Adaptimmune has strategic collaborations, notably with Genentech for allogeneic T-cell therapies, enhancing scalability. Partnerships with Universal Cells, Noile-Immune, Alpine Immune Sciences, and MD Anderson underscore their commitment to innovation. Founded in 2008, the company is based in the UK.

Ticker Symbol: ADAP, Exchange: NASDAQ, Type: common stock, Country Origin: United Kingdom, GICS Sub Industry: Biotechnology

Average Volume 20d: 993,213, Last Price: $0.48, SMA 20: $0.57, SMA 50: $0.59, SMA 200: $0.87, ATR: $0.05

Market Cap: $138.18M USD, P/E: 0.00, P/E Forward: 0.00, P/B: 1.75, P/S: 0.79, RoE: -56.17

3-Month Forecast: The stock may face short-term challenges, trading below its 20 and 50-day SMAs. Low ATR suggests limited volatility. Fundamental challenges include negative RoE and low P/S, indicating undervaluation. However, the robust pipeline and collaborations are positives. Overall, the outlook is neutral to bearish.